Abstract
We report five of 38 patients with stiff person syndrome (SPS), who also had cerebellar disease, gait ataxia, dysarthria, and oculomotor dysfunction (SPS-Cer). Cerebellar manifestations either preceded SPS or occurred concurrently. Brain MRI was normal. The intrathecal production of glutamic acid decarboxylase antibodies was elevated. γ-Aminobutyric acid-enhancing drugs and immunotherapies improved only the stiffness. SPS-Cer is a distinct subset of SPS causing a more severe and complex clinical phenotype.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1068-1070 |
| Number of pages | 3 |
| Journal | Neurology |
| Volume | 67 |
| Issue number | 6 |
| DOIs | |
| State | Published - Sep 1 2006 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
Cite this
Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. / Rakocevic, Goran; Raju, Raghavan Pillai; Semino-Mora, Cristina; Dalakas, Marinos C.
In: Neurology, Vol. 67, No. 6, 01.09.2006, p. 1068-1070.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies
AU - Rakocevic, Goran
AU - Raju, Raghavan Pillai
AU - Semino-Mora, Cristina
AU - Dalakas, Marinos C.
PY - 2006/9/1
Y1 - 2006/9/1
N2 - We report five of 38 patients with stiff person syndrome (SPS), who also had cerebellar disease, gait ataxia, dysarthria, and oculomotor dysfunction (SPS-Cer). Cerebellar manifestations either preceded SPS or occurred concurrently. Brain MRI was normal. The intrathecal production of glutamic acid decarboxylase antibodies was elevated. γ-Aminobutyric acid-enhancing drugs and immunotherapies improved only the stiffness. SPS-Cer is a distinct subset of SPS causing a more severe and complex clinical phenotype.
AB - We report five of 38 patients with stiff person syndrome (SPS), who also had cerebellar disease, gait ataxia, dysarthria, and oculomotor dysfunction (SPS-Cer). Cerebellar manifestations either preceded SPS or occurred concurrently. Brain MRI was normal. The intrathecal production of glutamic acid decarboxylase antibodies was elevated. γ-Aminobutyric acid-enhancing drugs and immunotherapies improved only the stiffness. SPS-Cer is a distinct subset of SPS causing a more severe and complex clinical phenotype.
UR - http://www.scopus.com/inward/record.url?scp=33748984274&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748984274&partnerID=8YFLogxK
U2 - 10.1212/01.wnl.0000237558.83349.d0
DO - 10.1212/01.wnl.0000237558.83349.d0
M3 - Article
C2 - 17000981
AN - SCOPUS:33748984274
VL - 67
SP - 1068
EP - 1070
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 6
ER -